ArticleCancer medicine2026
Adjuvant Imatinib for Patients Resected for GIST: A Quality Assurance Study.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe administration of adjuvant Imatinib for three years is a standard care of treatment in Denmark and indicated after resection of GIST with high and intermediate risk of recurrence. There are no reported real-world data on the safety of the treatment and the impact of adjusted treatment for the outcome of recurrence.
methodsThis is a retrospective study quality assuring the tolerability of three-year treatment and amplify this duration effective to reduce the risk of relapse. The primary endpoint is to assure the safety of the treatment. Secondary endpoints are recurrence-free-survival and overall survival.
resultsFrom January 1st 2019 to 31st December 2023, 225 patients were collected, 71 were referred to adjuvant treatment. Further six patients were excluded due to a short follow-up, ending with 65 eligible patients for inclusion. In a median follow-up of three years, a total of 60% were reduced in dosage due to toxicity, majority continuing with 400 mg and 17% were interrupted due to toxicity. There was no significant difference in the group of recurrence and treatment reduction or interruption. A total of 23% had relapse with a median time from diagnosis to recurrence of 4.5 years.
interpretationThree years of adjuvant Imatinib is a tolerable duration with no significant rate of recurrence among patients who were reduced or interrupted in treatment due to toxicity. This study reports a significance between high mitotic index and the relapse rate and a relation between recurrence and tumor site, tumor size and KIT exon 9 mutation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.